Business
AVROBIO Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a
About this update from Tectonic Therapeutic, Inc.
[{"type":"text","content":" CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced the appointment of Sean O’Bryan as chief regulatory officer. Sean brings a wealth of experience in regulatory strategy and product development to AVROBIO, as well as keen insight into the field of cell and gene therapy, where he has spent most of his career.\n\n“We are delighted to bring Sean O’Bryan on board as we advance multiple programs in lysosomal disorders. His leadership and deep understanding of the cell and gene therapy space will be highly valuable as we progress our clinical programs in cystinosis and Gaucher disease and move our other indications forward,” said Geoff MacKay, AVROBIO’s president and chief executive officer.\n\nO’Bryan has more 30 years of experience leading regulatory efforts in the biotech industry. He joins AVROBIO from Freeline Therapeutics, where he served as the senior vice president and head of Global Regulatory Affairs. During his tenure, O’Bryan directed the development of gene therapies from preclinical to clinical and managed CMC strategy generation and execution as well as negotiations and approvals with global agencies.\n\n“I am thrilled to land at AVROBIO and join this incredibly talented and dedicated team,” said O’Bryan. “I look forward to leveraging my product development and regulatory expertise to make AVROBIO’s vision – to bring personalized gene therapy to the world – a reality for the patients and families we serve.”\n\nPreviously, O’Bryan was senior vice president, head of Regulatory Affairs & Quality Assurance at Axovant (now Sio Gene Therapies), leading all regulatory and quality work for multiple vector-based gene therapy programs and serving as project lead for the lysosomal disease programs. He also advanced the regulatory process for multiple cell and gene therapy programs in his previous roles as vice president, head of Regulatory Affairs and Quality Assurance at Lysogene, senior director of Regulatory Affairs and head of Regulatory CMC at bluebird bio and director, Regulatory Affairs at Sanofi/Genzyme. O’Bryan holds a B.S. from Boston University.\n\nAbout AVROBIO\nOur vision is to bring personalized gene therapy to the world. We aim to prevent, halt or reverse disease thr...